Ipsc-derived cardiomyocytes for studying genetically induced cardiomyopathies
Leveraging iPSC-derived cardiomyocytes from patients with genetic cardiomyopathies, this research offers a platform for novel therapeutic development by recapitulating patient-specific cardiac pathologies.
Overview
This innovative research utilizes induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) from patients with genetically induced cardiomyopathies. By mimicking patient-specific cardiac pathologies, these iPSC-CMs serve as a powerful tool for developing novel therapies. The platform enables detailed examination of cellular and molecular features, providing insights into potential therapeutic targets for conditions such as Duchenne Muscular Dystrophy (DMD) and other mutations affecting titin and lamin (LMNA) genes.
Technical specifications
The research employs a variety of advanced techniques to analyze iPSC-CMs, including:
- Electrophysiological assessments: Single-cell action potentials and ionic currents using patch clamp techniques, extracellular electrograms via MEA.
- Calcium and contraction analysis: Using Fura-2 for calcium transients and video edge detection for contractions.
- Metabolic profiling: SeaHorse Flux analyzer for oxidative phosphorylation and glycolysis, along with LC/MS for comprehensive metabolomics.
- Intercellular coupling: Lucifer Yellow dye transfer.
- Molecular and genetic analysis: Confocal microscopy, Western blotting, RT-PCR, and RNA-Seq. These methodologies allow for a comprehensive understanding of cardiomyocyte function and pathology at a cellular level.
Technology readiness level
This technology is at TRL 4, having been validated in laboratory settings with documented success in recapitulating patient-specific cardiac pathologies. Collaborative opportunities with pharmaceutical companies could further advance its development and application in therapeutic research.
About Technion - Israel Institute of Technology
Technion – Israel Institute of Technology is a leading public technological university in Haifa with a STEM‑intensive, entrepreneurial culture and a globally engaged research community. Companies engage via co‑located labs and shared core facilities on campus, with access to prototyping and fabrication shops and contract research. The medical faculty’s integration with major teaching hospitals enables clinical studies and translation, and the campus lies within Israel’s high‑tech corridor, linking partners to startups and multinational R&D centers. Research is backed by national funding from the Israel Science Foundation and the Israel Innovation Authority, plus European programs like Horizon Europe and binational foundations; a dedicated technology transfer office supports IP, licensing, and startup formation.
delivered to your inbox.